Pulmonary function and chest computed tomography abnormalities 6–12 months after recovery from COVID-19: a systematic review and meta-analysis

Abstract

Background Some coronavirus disease 2019 (COVID-19) survivors experience prolonged and varying symptoms, a condition termed post-acute COVID-19 syndrome (PACS). However, the prevalence of chronic pulmonary sequelae of PACS during long-term follow-up remains unclear. Several studies have examined this issue and reported heterogeneous results. Methods We conducted a systematic review and meta-analysis using a random-effects model to estimate the pooled prevalence of the pulmonary sequelae of COVID-19, as demonstrated by pulmonary function testing (PFT) and chest computed tomography (CT) performed at least 6 months after initial infection. PubMed, Embase, and Cochrane Library databases were searched from January 1, 2020 to December 31, 2021 to identify related studies. We investigated whether the prevalence of pulmonary sequelae decreased over time and attempted to identify the factors associated with their development by performing multiple subgroup and meta-regression analyses. Results Of the 18,062 studies identified, 30 met our eligibility criteria. Among these studies, 25 and 22 had follow-up PFT and chest CT data, respectively. The follow-up durations were approximately 6 and 12 months in 18 and 12 studies, respectively. Impaired diffusion capacity was the most common abnormality on PFT (pooled prevalence 35%, 95% confidence interval [CI] 30–41%) with a prevalence of 39% (95% CI 34–45%) and 31% (95% CI 21–40%) in the 6-month and 12-month follow-up studies, respectively (P = 0.115). Restrictive pulmonary dysfunction evident as reduced forced vital capacity was less frequent (pooled prevalence 8%, 95% CI 6–11%); however, its prevalence was lower in the 12-month follow-up studies than in the 6-month follow-up studies (5% [95% CI 3–7%] vs. 13% [95% CI 8–19%], P = 0.006). On follow-up chest CT, the pooled prevalence of persistent ground-glass opacities and pulmonary fibrosis was 34% (95% CI 24–44%) and 32% (95% CI 23–40%), respectively, and the prevalence did not decrease over time. As every meta-analysis showed significant between-study heterogeneity, subgroup and meta-regression analyses were performed to identify potential effect modifiers; the severity of index infection was associated with the prevalence of impaired diffusion capacity and pulmonary fibrosis. Conclusions A substantial number of COVID-19 survivors displayed pulmonary sequelae as part of PACS. Except for restrictive pulmonary dysfunction, the prevalence of these sequelae did not decrease until 1 year after initial infection. Considering the association between the severity of acute COVID-19 and risk of pulmonary sequelae, patients who recover from severe COVID-19 require close respiratory follow-up. Systematic review registration number PROSPERO CRD42021234357

N-acetylcysteine Reduces Inflammasome Activation Induced by SARS-CoV-2 Proteins In Vitro

“…In fact, serum levels of antioxidant thiols and GSH, among others, are decreased and inversely correlated with COVID-19 severity, while reactive nitric and oxygen species are overexpressed and correlated with COVID-19 severity [ 45 ]. In this work, we evaluated the expression and the balance between the anti-oxidant transcription factor Nrf2 and the oxidant NOX4 cell membrane protein since the increase in NOX4/Nrf2 ratio has been associated with lung fibrosis [ 46 ], important sequelae of COVID-19 [ 47 ]. We observed an increase in Nrf2 and NOX4 expression in tracheal epithelial cells and infiltrated inflammatory cells, but an increased NOX4/Nrf2 redox imbalance, suggesting that the overexpression of the reactive oxygen species-generating enzyme NOX4 overcame the capacity to induce the Nrf2 as previously outlined in patients with lung fibrosis [ 46 ].…”

Prediction Value of KREBS Von Den Lungen-6 (KL-6) Biomarker in COVID-19 Patients: A Systematic Review and Meta-Analysis

“…Therefore, KL-6 with the predictive value would predict who will be more likely to experience the fibrosing gradually, which can also be very helpful in assessing the COVID-19 patient’s condition, organizing the treatment for pulmonary fibrosis, or determining fibrosis following COVID-19 after the patient has been discharged from the hospital. This is crucial since 32–44.9% of individuals will develop lung fibrosis following COVID-19 [ 34 , 35 ]. Moreover, previous research has shown that the length of the illness plays a significant role in predicting the development of lung fibrosis following ARDS.…”

“Long Haulers”

“…The severity of index infection was associated with the presence of pulmonary fibrosis and impairments in diffusion capacity. 75 Specific radiographic patterns of pulmonary fibrosis have been reported. Besutti published findings derived from a cohort of 405 Italian patients 5 to 7 months after hospitalization; 55% of patients were normal while 37.5% demonstrated nonfibrotic (predominantly ground glass opacities consistent with nonspecific interstitial pneumonia with or without organizing pneumonia) and 4.4% demonstrated fibrotic abnormalities (subpleural reticulation, traction bronchiectasis and ground glass consistent with fibrotic nonspecific interstitial pneumonia).…”

“…The severity of index infection was associated with the presence of pulmonary fibrosis and impairments in diffusion capacity. 75…”